EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 179 filers reported holding EAGLE PHARMACEUTICALS INC in Q4 2019. The put-call ratio across all filers is 0.16 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $312,779 | +95844.5% | 11,025 | -1.1% | 0.00% | 0.0% |
| Q4 2022 | $326 | -99.9% | 11,144 | +15.1% | 0.00% | 0.0% |
| Q3 2022 | $256,000 | -43.5% | 9,683 | -4.9% | 0.00% | -40.0% |
| Q2 2022 | $453,000 | -6.6% | 10,187 | +4.0% | 0.01% | 0.0% |
| Q1 2022 | $485,000 | +11.0% | 9,797 | +14.1% | 0.01% | 0.0% |
| Q4 2021 | $437,000 | -10.3% | 8,589 | -1.7% | 0.01% | -16.7% |
| Q3 2021 | $487,000 | +27.2% | 8,739 | -2.4% | 0.01% | +50.0% |
| Q2 2021 | $383,000 | +2.7% | 8,953 | +0.1% | 0.00% | -20.0% |
| Q1 2021 | $373,000 | -10.8% | 8,943 | -0.4% | 0.01% | -16.7% |
| Q4 2020 | $418,000 | +4.8% | 8,983 | -4.4% | 0.01% | -25.0% |
| Q3 2020 | $399,000 | +62.9% | 9,397 | +84.3% | 0.01% | +60.0% |
| Q2 2020 | $245,000 | +4.7% | 5,098 | +0.2% | 0.01% | 0.0% |
| Q1 2020 | $234,000 | +13.6% | 5,090 | +48.4% | 0.01% | +25.0% |
| Q4 2019 | $206,000 | – | 3,430 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 121,014 | $5,377,000 | 1.78% |
| Smith, Graham & Co., Investment Advisors, LP | 232,343 | $10,323,000 | 1.28% |
| GLOBEFLEX CAPITAL L P | 73,205 | $3,252,000 | 0.79% |
| SummerHaven Investment Management, LLC | 18,604 | $827,000 | 0.56% |
| BRANDES INVESTMENT PARTNERS, LP | 464,292 | $20,628,000 | 0.50% |
| Capital Impact Advisors, LLC | 11,728 | $521,000 | 0.48% |
| Watershed Asset Management, L.L.C. | 5,756 | $256,000 | 0.32% |
| Foundry Partners, LLC | 84,325 | $3,747,000 | 0.23% |
| Summit Global Investments | 33,738 | $1,499,000 | 0.13% |
| SCOUT INVESTMENTS, INC. | 147,034 | $6,533,000 | 0.13% |